Gilead Sciences, Inc. · Foster City, CA United States (NASDAQ: GILD)
Key Gilead Sciences, Inc. Financials
| Company Type | Public -(NASDAQ: GILD) Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2001 Sales (mil.) | $233.8 |
| 2010 Employees | 4,000 |
Gilead Sciences, Inc. Income Statement
| Dec 01 | Dec 00 | Dec 99 | |
| Revenue | 233.8 | 195.6 | 169.0 |
| Cost of Goods Sold | 43.8 | 21.5 | 29.5 |
| Gross Profit | 190.0 | 174.1 | 139.4 |
| Gross Profit Margin | 81.3% | 89% | 82.5% |
| SG&A Expense | 125.1 | 82.8 | 78.3 |
| Depreciation & Amortization | 14.7 | 12.0 | 12.6 |
| Operating Income | (120.7) | (52.3) | (54.4) |
| Operating Margin | -51.6% | -26.8% | -32.2% |
| Nonoperating Income | 164.4 | (2.9) | 0.0 |
| Nonoperating Expenses | -- | -- | -- |
| Income Before Taxes | 57.4 | -- | (60.9) |
| Income Taxes | 4.1 | 1.2 | 0.9 |
| Net Income After Taxes | 53.3 | (1.2) | (61.8) |
| Continuing Operations | 51.2 | (43.1) | (66.5) |
| Discontinued Operations | -- | -- | -- |
| Total Operations | 51.2 | (43.1) | (66.5) |
| Total Net Income | 52.3 | (43.1) | (66.5) |
| Net Profit Margin | 22.4% | -22% | -39.3% |
| Diluted EPS from Total Net Income | 0.07 | (0.08) | (0.10) |
| Dividends per Share | -- | -- | 0.0 |
All amounts in millions of US Dollars except per share amounts.
Gilead Sciences, Inc. Balance Sheet
| Assets | Dec 01 | Dec 00 | Dec 99 |
| Current Assets | |||
| Cash | 162.3 | 197.3 | 47.0 |
| Net Receivables | 74.2 | 48.8 | 45.6 |
| Inventories | 39.3 | 20.6 | 21.0 |
| Other Current Assets | 431.9 | 327.1 | 258.4 |
| Total Current Assets | 707.8 | 593.8 | 372.0 |
| Net Fixed Assets | 62.8 | 55.2 | 51.4 |
| Other Noncurrent Assets | 24.2 | 29.1 | 13.4 |
| Total Assets | 794.8 | 678.1 | 436.8 |
| Liabilities | Dec 01 | Dec 00 | Dec 99 |
| Current Liabilities | |||
| Accounts Payable | 19.2 | 11.6 | 9.5 |
| Short-Term Debt | 1.5 | 3.0 | 3.2 |
| Other Current Liabilities | 59.5 | 43.6 | 35.2 |
| Total Current Liabilities | 80.1 | 58.2 | 47.9 |
| Long-Term Debt | 250.4 | 252.2 | 84.8 |
| Other Noncurrent Liabilities | 11.8 | 16.5 | 6.9 |
| Total Liabilities | 342.3 | 327.0 | 139.5 |
| Shareholder's Equity | |||
| Preferred Stock Equity | -- | -- | 0.0 |
| Common Stock Equity | 452.4 | 351.1 | 297.3 |
| Total Equity | 452.4 | 351.1 | 297.3 |
| Shares Outstanding (thou.) | 767,551.5 | 811,867.7 | 899,925.1 |
All amounts in millions of US Dollars except per share amounts.
Gilead Sciences, Inc. Cash Flow Statement
| Dec 01 | Dec 00 | Dec 99 | |
| Net Operating Cash Flow | (88) | (38) | (63) |
| Net Investing Cash Flow | 20.8 | (84.2) | (16.3) |
| Net Financing Cash Flow | 33.6 | 269.0 | 24.0 |
| Net Change in Cash | (35.0) | 150.3 | (54.1) |
| Depreciation & Amortization | 14.7 | 12.0 | 12.6 |
| Capital Expenditures | (26.3) | (15.6) | (12.5) |
| Cash Dividends Paid |
All amounts in millions of US Dollars except per share amounts.